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Metformin is biquanid which, during its therapeutic use, has undergone a period of perdition 
and fall followed by again rising up to the imaginary pharmacological-therapeutic summit 
when it became a “gold standard” in the treatment of patients with type 2 diabetes mellitus. 
Currently, it is recommended by the professional authorities abroad and in the Czech 
Republic as a first choice drug after determination of diagnosis together with diet and 
physical exercise. 
How these recommendations follow and reflect the diabetological prescription situation? 
What prevents the physicians-prescriptors from implementation of the recommendations into 
their daily practice?  
The aim and subject of this thesis is the issue of therapy of type 2 diabetes mellitus (DM) by 
means of oral antidiabetics (PADs) with a special focus on the decision mechanisms of 
selected prescription groups of physicians. A historical development of metformin must be 
reminded in the theoretical part of this thesis in order to better understand and substantiate 
these prescription habits, and furthermore a development and changes of its position in the 
professional recommendations (guidelines) as well as a development regarding the growth of 
its consumption on the Czech pharmaceutical market which reflects the real use of this drug 
in the medical practice. 
Therefore, the practical part of this thesis is aimed at the analysis of postures and 
motivations of prescriptors-diabetologists and general practitioners for selection and 
indication of PADs in a patient with type 2 DM. This analysis reflects in detail the results 
obtained in June 2006. 
The issue of initiation of therapy of a diabetic patient with type 2 DM with a PAD is very 
complex and cannot be elucidated by one or several sentences. It has to be viewed within 
the overall patient - physician - professional society - health-care insurance company - 
pharmaceutical company/manufacturer context.  
This thesis does not take into account the issue of the costs of a physician-prescriptor for the 
therapy with PADs.  
 
 
 
 
